Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus DEMECLOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus DEMECLOCYCLINE HYDROCHLORIDE.
AUREOMYCIN vs DEMECLOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic